Amphastar Pharmaceuticals (NASDAQ:AMPH) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Tuesday, ValuEngine reports.

Several other equities analysts have also recently commented on AMPH. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. TheStreet cut Amphastar Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, November 7th. Finally, BidaskClub raised Amphastar Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, November 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $24.05.

Amphastar Pharmaceuticals stock opened at $19.04 on Tuesday. The business has a 50 day moving average price of $19.03 and a two-hundred day moving average price of $20.25. The company has a quick ratio of 1.84, a current ratio of 3.11 and a debt-to-equity ratio of 0.13. The stock has a market cap of $915.76 million, a price-to-earnings ratio of 90.67 and a beta of 1.16. Amphastar Pharmaceuticals has a 12 month low of $16.71 and a 12 month high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.08 by $0.02. The firm had revenue of $80.14 million during the quarter, compared to analysts’ expectations of $78.53 million. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.12 EPS. On average, analysts expect that Amphastar Pharmaceuticals will post 0.05 earnings per share for the current fiscal year.

In other news, CEO Jack Y. Zhang sold 300,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $20.82, for a total value of $6,246,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,147,316 shares of the company’s stock, valued at approximately $44,707,119.12. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Jason B. Shandell sold 7,340 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $21.32, for a total value of $156,488.80. Following the completion of the transaction, the general counsel now directly owns 147,103 shares of the company’s stock, valued at $3,136,235.96. The disclosure for this sale can be found here. In the last ninety days, insiders sold 323,155 shares of company stock valued at $6,742,840. Insiders own 30.80% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of AMPH. Acadian Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $88,000. Bank of Montreal Can raised its holdings in shares of Amphastar Pharmaceuticals by 130.7% in the 2nd quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after buying an additional 2,789 shares in the last quarter. Magnus Financial Group LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $204,000. JPMorgan Chase & Co. raised its holdings in shares of Amphastar Pharmaceuticals by 15.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $208,000. 51.82% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.